Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy

14Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Platinum-based neoadjuvant chemotherapy followed by interval debulking surgery is an accepted treatment for patients with stage III or IV epithelial ovarian cancer who are not suitable for primary debulking surgery. The identification of suitable adjuvant treatments in these patients is an unmet need. Here, we explore potential genomic characteristics (mutational and immune-associated expression profiles) in a series of patients undergoing neoadjuvant chemotherapy. Tumor samples from biopsy and interval debulking surgery were analyzed for mutational landscape and immune profiling, together with detailed immunohistochemistry using different immune cell markers, and correlated with clinicopathological characteristics and potential response to neoadjuvant chemotherapy. No major differences in the mutational landscape were observed in paired biopsy and surgery samples. Genomic loss of heterozygosity was found to be higher in patients with total/near-total tumor response. The immune gene expression profile after neoadjuvant chemotherapy revealed activation of several immune regulation-related pathways in patients with no/minimal or partial response. In parallel, neoadjuvant therapy caused a significant increase of tumor-infiltrating lymphocyte population abundance, primarily due to an augmentation of the CD8+ T cell population. Remarkably, these changes occurred irrespective of potential homologous recombination defects, such as those associated with BRCA1/2 mutations. Our study strengthens the use of loss of heterozygosity as a biomarker of homologous repair deficiency. The changes of immune states during neoadjuvant chemotherapy reveal the dynamic nature of tumor-host immune interactions and suggest the potential use of immune checkpoint inhibitors or their combination with poly-ADP polymerase inhibitors in high stage and grade epithelial ovarian cancer patients undergoing neoadjuvant therapy.

References Powered by Scopus

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

67336Citations
N/AReaders
Get full text

Integrated genomic analyses of ovarian carcinoma

6280Citations
N/AReaders
Get full text

COSMIC: The Catalogue Of Somatic Mutations In Cancer

3104Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?

10Citations
N/AReaders
Get full text

The current trend of exosome in epithelial ovarian cancer studies: A bibliometric review

9Citations
N/AReaders
Get full text

Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways

8Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Lodewijk, I., Bernardini, A., Suárez-Cabrera, C., Bernal, E., Sánchez, R., Garcia, J. L., … Manso, L. (2022). Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy. Npj Precision Oncology, 6(1). https://doi.org/10.1038/s41698-021-00247-3

Readers' Seniority

Tooltip

Researcher 6

50%

PhD / Post grad / Masters / Doc 5

42%

Professor / Associate Prof. 1

8%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 4

31%

Medicine and Dentistry 4

31%

Biochemistry, Genetics and Molecular Bi... 3

23%

Engineering 2

15%

Save time finding and organizing research with Mendeley

Sign up for free